Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. It is conducting a Phase I clinical trial of its lead product candidate, IPI-504, a novel, proprietary small molecule inhibitor of Hsp90, in patients with Gleevec-refractory gastrointestinal stromal tumors, as well as a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company is also analyzing data from its Phase I clinical trial of IPI-504 in patients with refractory multiple myeloma. In addition, it focuses on the development and commercialization of cancer drugs targeting the Hedgehog pathway, as well as on the identification of small molecule compounds that inhibit the Bcl-2 family of proteins. The company has a product development and commercialization agreement with MedImmune, Inc. to jointly develop and commercialize novel small molecule cancer drugs, including IPI-504, targeting Hsp90, as well as those targeting the Hedgehog pathway; and with Novartis Institutes of BioMedical Research to discover, develop, and commercialize drugs targeting the Bcl family of proteins. Infinity Pharmaceuticals is based in Cambridge, Massachusetts.
<img alt="" data-cke-saved-src="http://stockcharts.com/c-sc/sc?s=infi&p=D&yr=0&mn=4&dy=0&i=p31506003373&a=81927329&r=373" src="http://stockcharts.com/c-sc/sc?s=infi&p=D&yr=0&mn=4&dy=0&i=p31506003373&a=81927329&r=373" %3e"="">